Pharma major Cipla Ltd rose 0.38% to Rs 594 at mid-noon on BSE after the company stated that it has obtained final approval for generic Epzicom tablets. The announcement was made on 4 April 2017, when the markets were shut on account of local holiday.
On the BSE, 1.08 lakh shares have been traded in the counter in the volatile trade, compared with the ADV (average daily volume) of 1.16 lakh shares in the past one quarter. The stock had hit a high and low of Rs 600.55 and Rs 593.25 respectively during the day.
Cipla stock had underperformed the market over the past one month till 3 April 2017, gaining 0.71 % compared with 3.74% rise of Sensex. The scrip further underperformed the market in past one quarter, growing 3.07% as against 12.26% gain of Sensex.
The consolidated net profit of Cipla Ltd rose 43.85% to Rs. 374.83 Cr, on 15.64% rise in net sales to Rs, 3,550.02 crore in quarter third December 2016 Year-on-year.
This entry was posted in Commodity Market, Currency Market, Equity Market, Future Market, MCX Gold Live Updates and Trading Tips, Money Maker Financial Video, NCDEX Cardamom futures Live Updates Free, Option Market, Services and tagged /share market tips, bse nse tips, Cipla Pharma, free stock tips, future and option tips, Future trading tips, hot stock tips calls, Intraday tips, Investment Advisory Services, Money Maker Research, nifty intraday trading tips, nifty trading tips.